MAZZARELLA, LUCA
 Distribuzione geografica
Continente #
EU - Europa 3.668
AS - Asia 3.582
NA - Nord America 2.989
SA - Sud America 294
AF - Africa 73
OC - Oceania 41
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.648
Nazione #
US - Stati Uniti d'America 2.856
CN - Cina 1.556
DE - Germania 1.451
SG - Singapore 682
IT - Italia 653
GB - Regno Unito 441
HK - Hong Kong 308
BR - Brasile 221
VN - Vietnam 216
FR - Francia 206
RU - Federazione Russa 194
JP - Giappone 188
SE - Svezia 166
IN - India 158
CA - Canada 92
FI - Finlandia 90
NL - Olanda 88
TR - Turchia 87
KR - Corea 82
ES - Italia 71
IE - Irlanda 71
TW - Taiwan 71
BD - Bangladesh 55
ID - Indonesia 51
AT - Austria 36
AU - Australia 36
DK - Danimarca 35
CI - Costa d'Avorio 29
PL - Polonia 27
BE - Belgio 25
MX - Messico 25
PH - Filippine 21
CH - Svizzera 20
UA - Ucraina 15
AR - Argentina 14
HU - Ungheria 14
TH - Thailandia 14
CL - Cile 13
PE - Perù 12
PT - Portogallo 12
CZ - Repubblica Ceca 11
IQ - Iraq 11
EC - Ecuador 10
GR - Grecia 10
JO - Giordania 10
AE - Emirati Arabi Uniti 8
EG - Egitto 8
IL - Israele 8
RO - Romania 8
SA - Arabia Saudita 8
CO - Colombia 7
IR - Iran 7
UZ - Uzbekistan 7
ZA - Sudafrica 7
TN - Tunisia 6
VE - Venezuela 6
BG - Bulgaria 5
CY - Cipro 5
HR - Croazia 5
MA - Marocco 5
MV - Maldive 5
MY - Malesia 5
NZ - Nuova Zelanda 5
PY - Paraguay 5
EU - Europa 4
GE - Georgia 4
GT - Guatemala 4
KE - Kenya 4
NG - Nigeria 4
PK - Pakistan 4
UY - Uruguay 4
NP - Nepal 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
BO - Bolivia 2
CG - Congo 2
CR - Costa Rica 2
JM - Giamaica 2
LT - Lituania 2
LY - Libia 2
PA - Panama 2
SN - Senegal 2
TT - Trinidad e Tobago 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AP - ???statistics.table.value.countryCode.AP??? 1
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BS - Bahamas 1
BY - Bielorussia 1
CU - Cuba 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
HN - Honduras 1
KW - Kuwait 1
KZ - Kazakistan 1
Totale 10.646
Città #
Frankfurt am Main 1.168
Singapore 382
Ashburn 331
Southend 254
Hong Kong 219
Milan 189
Chandler 181
Beijing 162
Shanghai 162
Dallas 160
San Jose 137
Fairfield 128
Hefei 118
Redwood City 117
Los Angeles 87
Seattle 84
Council Bluffs 81
Guangzhou 77
Hanoi 73
Wilmington 71
Woodbridge 69
Nanjing 68
Houston 66
New York 66
Dublin 62
Ho Chi Minh City 62
Dearborn 60
Princeton 58
Helsinki 53
Santa Clara 52
Cambridge 50
Tokyo 50
Bengaluru 49
Ann Arbor 48
Munich 40
Moscow 38
Jakarta 37
Lauterbourg 37
Taipei 37
Seoul 36
Shenyang 35
Hangzhou 34
Istanbul 34
Buffalo 33
London 33
Chengdu 32
Abidjan 29
Wuhan 29
Rome 28
Naples 27
Toronto 27
Cangzhou 26
Ottawa 25
Boardman 24
Jinan 23
Zhengzhou 23
Madrid 22
Phoenix 20
Berlin 19
São Paulo 19
Des Moines 18
Vienna 18
Washington 18
Ankara 17
Nanchang 17
Paris 17
Da Nang 15
San Diego 15
The Dalles 15
Qingdao 14
Bari 13
Chicago 13
Düsseldorf 13
Mumbai 13
Redmond 13
Columbus 12
Florence 12
Fuzhou 12
Hyderabad 12
Oulu 12
Springe 12
Brussels 11
Central 11
Changsha 11
Nuremberg 11
Shenzhen 11
Turku 11
Boston 10
Lima 10
Rio de Janeiro 10
Tianjin 10
Bologna 9
Chennai 9
Chongqing 9
Matsuyama 9
Montpellier 9
Mountain View 9
Padua 9
Porto Alegre 9
Santiago 9
Totale 6.249
Nome #
Cetuximab for treating non-small cell lung cancer 2.221
Entinostat for the treatment of breast cancer 891
Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients 419
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis 410
p53 Loss in Breast Cancer Leads to Myc Activation, Increased Cell Plasticity, and Expression of a Mitotic Signature with Prognostic Value 387
Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis 356
Cytotoxic effect of (1-methyl-1H-imidazol-2-yl)-methanamine and its derivatives in PtII complexes on human carcinoma cell lines: A comparative study with cisplatin 311
Machine learning-based reclassification of germline variants of unknown significance: The RENOVO algorithm 275
DOTS-Finder : a comprehensive tool for assessing driver genes in cancer genomes 253
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis 240
The Challenge of Choosing the Best Classification Method in Radiomic Analyses: Recommendations and Applications to Lung Cancer CT Images 237
A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer data 235
Mapping functional to morphological variation reveals the basis of regional extracellular matrix subversion and nerve invasion in pancreatic cancer 216
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population 215
Liver toxicity in the era of immune checkpoint inhibitors: A practical approach 214
High-Fat Diet Promotes Acute Promyelocytic Leukemia through PPARδ-Enhanced Self-renewal of Preleukemic Progenitors 210
Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion 210
Master protocols in immuno-oncology : Do novel drugs deserve novel designs? 207
The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review 199
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges 198
Semantic and geographical analysis of COVID-19 trials reveals a fragmented clinical research landscape likely to impair informativeness 193
TMBleR, a bioinformatic tool to optimize TMB estimation and predictive power 193
High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias 192
Inhibition of the lysine demethylase LSD1 modulates the balance between inflammatory and antiviral responses against coronaviruses 192
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population 191
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer 187
Prospective validation of the Italian alliance against cancer lung panel in patients with advanced non–small-cell lung cancer 185
Precision Trial Drawer, a Computational Tool to Assist Planning of Genomics-Driven Trials in Oncology 185
Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols 183
Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial 171
Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: Back to the future? 158
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience 137
Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity 136
Detection of clustered circulating tumour cells in early breast cancer 136
Pharmacological management of male breast cancer 129
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population 118
The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality 116
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience 108
A new approach to assess drug sensitivity in cells for novel drug discovery 92
Corrigendum to: "Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis" [Eur J Cancer 145 (2021) 197-209] 1
Totale 10.907
Categoria #
all - tutte 25.238
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.238


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021163 0 0 0 0 0 0 0 0 0 0 88 75
2021/2022787 66 71 60 62 62 56 81 43 95 46 46 99
2022/2023837 78 81 82 63 90 128 37 53 95 38 43 49
2023/20241.703 49 71 47 78 135 105 237 190 124 190 232 245
2024/20252.324 207 240 192 245 133 105 114 222 138 200 206 322
2025/20262.874 319 341 357 248 218 154 474 103 257 189 214 0
Totale 10.907